Heidi Roschitzki‐Voser

Author

Frontier Science Foundation-Hellas ORCID

Also Known As

H. Roschitzki-Voser, Heidi Roschitzki-Voser, Heidi Roschitzki‐Voser

Publications

1.8K

Citations

H-Index

Concepts

All Affiliations

Frontier Science Foundation-Hellas University Hospital of Zurich University Hospital of Lausanne National and Kapodistrian University of Athens Institut Català d'Oncologia

About

Heidi Roschitzki‐Voser is an author at Frontier Science Foundation-Hellas specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	19	1.3K
2	Health Sciences	6	6	292
3	Biochemistry	3	3	237
4	Natural Sciences	2	2	198
5	Engineering	1	1	39

Heidi Roschitzki‐Voser

Publications

1.5K

Citations

H-Index

Page 1

	Year	Citations
A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial Sanjay Popat, Alessandra Curioni‐Fontecedro, Urania Dafni, Annals of Oncology	2020	265
Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer—The ETOP NICOLAS trial Solange Peters, Enriqueta Felip, Urania Dafni, Lung Cancer Radiation MedicineRadiation TherapyMedicineMetronomic TherapyClinical Radiation Oncology	2019	159
Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP) Rafał Dziadziuszko, Egbert F. Smit, Urania Dafni, Journal of Thoracic Oncology	2019	147
Inhibition of Caspase-2 by a Designed Ankyrin Repeat Protein: Specificity, Structure, and Inhibition Mechanism Andreas Schweizer, Heidi Roschitzki‐Voser, Patrick Amstutz, Structure Protein FunctionSignal TransductionInhibition MechanismBiochemistryG Protein-coupled Receptor	2007	130
Progression-Free and Overall Survival for Concurrent Nivolumab With Standard Concurrent Chemoradiotherapy in Locally Advanced Stage IIIA-B NSCLC: Results From the European Thoracic Oncology Platform NICOLAS Phase II Trial (European Thoracic Oncology Platform 6-14) Solange Peters, Enriqueta Felip, Urania Dafni, Journal of Thoracic Oncology Health SciencesRadiation TherapyOverall SurvivalMedicineConcurrent Nivolumab	2020	130
A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial Ross A. Soo, Ji‐Youn Han, Urania Dafni, Annals of Oncology Advanced NsclcBooster TrialNovel TherapyMedicinePathology	2021	111
Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy – results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial Solange Peters, Jean-Louis Pujol, Urania Dafni, Annals of Oncology OncologyImmune Checkpoint InhibitorConsolidation NivolumabCancer TreatmentIpilimumab Versus Observation	2021	105
Design, construction, and characterization of a second‐generation DARPin library with reduced hydrophobicity Markus A. Seeger, Andreas Flütsch, Petrus G. M. Gutte, Protein Science Crystal StructureProteinlipid InteractionReduced HydrophobicityProtein AssemblyMolecular Biology	2013	68
The Crystal Structure of Human Pyrin B30.2 Domain: Implications for Mutations Associated with Familial Mediterranean Fever Christopher Weinert, Christian Grütter, Heidi Roschitzki‐Voser, Journal of Molecular Biology Crystal StructureMutations AssociatedMedicineGeneticsProtein X-ray Crystallography	2009	65
A multicentre randomized phase III trial comparing pembrolizumab (P) vs single agent chemotherapy (CT) for advanced pre-treated malignant pleural mesothelioma (MPM): Results from the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial Sanjay Popat, Alessandra Curioni‐Fontecedro, Varvara Polydoropoulou, Annals of Oncology OncologyPhase Iii TrialClinical TrialsPleural DiseaseEtop 9-15	2019	54

Page 1